Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.

Published

Journal Article (Review)

The development of new therapies for castration-resistant prostate cancer (CRPC) has increasingly focused on improving patient quality of life, mainly because of limited survival gains and continuing high morbidity burden from disease progression or the adverse effects of treatments. However, there is no generally accepted quality of life instrument for use with this patient group. This paper objectively reviews the existing literature and assesses the impact of CRPC treatments on patients' quality of life. The review also provides a narrative description of the evolving role of quality of life measures in clinical trials, and critiques the most widely used instruments.

Full Text

Duke Authors

Cited Authors

  • Moul, JW; Dawson, N

Published Date

  • January 2012

Published In

Volume / Issue

  • 30 / 1

Start / End Page

  • 1 - 12

PubMed ID

  • 22236184

Pubmed Central ID

  • 22236184

Electronic International Standard Serial Number (EISSN)

  • 1532-4192

Digital Object Identifier (DOI)

  • 10.3109/07357907.2011.629381

Language

  • eng

Conference Location

  • England